Risk of Asthma Exacerbation, Asthma-Related Health Care Utilization and Costs, and Adherence to Controller Therapy in Patients with Asthma Receiving Fluticasone Propionate/Salmeterol Inhalation Powder 100 μg/50 μg Versus Mometasone Furoate Inhalation Powder

Journal of Asthma

Volumn 50, Issue 3, 2013, Pages 287-295

  Hagiwara, May ^a   Delea, Thomas E ^a   Stanford, Richard H ^b  

^a POLICY ANALYSIS INC PAI   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

Asthma; Exacerbation; Fluticasone propionate; Inhaled corticosteroids; Mometasone; Retrospective study; Salmeterol

Indexed keywords

FLUTICASONE PROPIONATE PLUS SALMETEROL; MOMETASONE FUROATE;

ARTICLE; ASTHMA; CLINICAL PRACTICE; COHORT ANALYSIS; CORTICOSTEROID THERAPY; DISEASE EXACERBATION; EMERGENCY WARD; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; ICD-9-CM; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTPATIENT CARE; PATIENT COMPLIANCE; POWDER INHALER; PRESCRIPTION; PROPENSITY SCORE; RETROSPECTIVE STUDY; SYSTEMIC THERAPY;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGED; ALBUTEROL; ANDROSTADIENES; ASTHMA; COHORT STUDIES; DELIVERY OF HEALTH CARE; DRUG COMBINATIONS; EMERGENCY SERVICE, HOSPITAL; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PREGNADIENEDIOLS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 84874884092     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2012.754028     Document Type: Article

References (20)

1. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma. Bethesda, MD: National Institutes of Health, 1997.
2. Global Initiative for Asthma. Global strategy for asthma management and prevention [database on the Internet]. National Institutes of Health and National Heart, Lung and Blood Institute. 2005. Available from: www.ginasthma.org
3. Campbell LM. Once-daily inhaled corticosteroids in mild to moderate asthma: Improving acceptance of treatment. Drugs 1999; 58(Suppl 4): 25-33, discussion 52. Epub 2000/03/11.
4. Kruse W, Rampmaier J, Ullrich G, Weber E. Patterns of drug compliance with medications to be taken once and twice daily assessed by continuous electronic monitoring in primary care. Int J Clin Pharmacol Ther 1994; 32(9):452-457, Epub 1994/09/01.
5. Diette GB, Wu AW, Skinner EA, Markson L, Clark RD, McDonald RC, Healy JPJr, Huber M, Steinwachs DM. Treatment patterns among adult patients with asthma: Factors associated with overuse of inhaled betaagonists and underuse of inhaled corticosteroids. Arch Intern Med 1999; 159:2679-2704.
6. Eisen SA, Miller DK, Woodward RS, Spitznagel E, Przybeck TR. The effect of prescribed daily dose frequency on patient medication compliance. Arch Intern Med 1990; 150(9):1881-1884, Epub 1990/09/01.
7. Mann M, Eliasson O, Patel K, ZuWallack RL. A comparison of the effects of bid and qid dosing on compliance with inhaled flunisolide. Chest 1992; 101(2):496-499.
8. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 2000; 343(5):332-336, Epub 2000/08/03.
9. Suissa S, Ernst P, Kezouh A. Regular use of inhaled corticosteroids and the long term prevention of hospitalisation for asthma. Thorax 2002; 57(10):880-884, Epub 2002/09/27.
10. Schatz M, Cook EF, Nakahiro R, Petitti D. Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma. J Allergy Clin Immunol 2003; 111(3):503-508, Epub 2003/03/19.
11. Boulet LP. Once-daily inhaled corticosteroids for the treatment of asthma. Curr Opin Pulm Med 2004; 10(1):15-21, Epub 2004/01/30.
12. Masoli M, Weatherall M, Holt S, Beasley R. Moderate dose inhaled corticosteroids plus salmeterol versus higher doses of inhaled corticosteroids in symptomatic asthma. Thorax 2005; 60(9):730-734, Epub 2005/09/02.
13. Tan RA, Corren J. Mometasone furoate in the management of asthma: A review. Ther Clin Risk Manag 2008; 4(6):1201-1208, Epub 2009/04/02.
14. Navaratnam P, Friedman HS, Urdaneta E. Mometasone furoate vs fluticasone propionate with salmeterol: Multivariate analysis of resource use and asthma-related charges. Curr Med Res Opin 2009; 25(12):2895- 2901, Epub 2009/10/14.
15. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992; 45(6):613-619, Epub 1992/06/01.
16. Rosenbaum PRD. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70:41-55.
17. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997; 127(8 Pt 2):757-763, Epub 1998/02/12.
18. Allison P. Survival Analysis Using the SAS System: A Practical Guide. Cary, NC: SAS Institute, Inc, 1995.
19. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. N Engl J Med 1997; 337 (20):1405-1411, Epub 1997/11/14.
20. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: A comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006; 129(1):15-26, Epub 2006/01/21.